IPDP2015 is active in the mouse FST (forced swim test), a model predictive for antidepressant-like activity in the clinic following acute drug administration. In agreement with both in vitro and in vivo measures of the ability to inhibit DA transporter function, IPDP2015 induced slow-on/slow-off increases in locomotor activity, indicating no abuse liability. As such it represents an attractive new drug candidate for the treatment of depression.

Major depression disorder also known as depression is a severe disorder with serious consequences. Some treatments are available; however, in clinical trials the majority of the patients fail to achieve a full therapeutic response. Furthermore, impairment from the disorder continues essentially unchanged in patients who are treated but do not fully remit. Clearly, alternatives are needed to manage this common clinical condition. Combination studies with SSRI´s and Bupropion improved treatment in antidepressant-resistant patients (reduction in the number & severity of symptoms), and reduced side-effects/adverse events (including reduction in sexual dysfunction).

IPDP2015 also worked well in rat models of persistent and neuropathic pain. Depression in patients with pain is associated with more pain complaints and greater impairment. Depression and pain share biological pathways and neurotransmitters, which has implications for the treatment of both concurrently. Treatment of depression and pain simultaneously is necessary for improved outcomes.